(BTSG) BrightSpring Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
BTSG: Home Healthcare, Pharmacy Services, Clinical Care
BrightSpring Health Services, Inc. (NASDAQ:BTSG) is a U.S.-based healthcare company that specializes in home and community-based care. Its platform integrates pharmacy and provider services, delivering clinical and supportive care to patients in non-facility settings. This model is increasingly important as the healthcare industry shifts toward cost-effective, value-based care. The company serves a diverse patient population, including those covered by Medicare, Medicaid, and private insurance, addressing the growing demand for accessible, patient-centric care.
Founded in 1974 and headquartered in Louisville, Kentucky, BrightSpring has built a robust network of clinical providers and pharmacists. Its services span home health, hospice care, and behavioral health, among others, making it a comprehensive player in the home healthcare space. The company’s focus on pharmacy services is particularly notable, as it plays a critical role in managing chronic diseases and improving patient outcomes. BrightSpring’s platform is well-positioned to benefit from the trend of healthcare moving into the home, a shift accelerated by technological advancements and changing patient preferences.
From a financial perspective, BrightSpring operates with a market capitalization of approximately $3.85 billion. The stock trades on the NASDAQ under the ticker symbol BTSG. With a forward P/E ratio of 51.28, the market is signaling expectations for significant future growth. The company’s price-to-sales ratio of 0.36 reflects its revenue generation relative to its market value, while the price-to-book ratio of 2.42 indicates that investors are valuing its intangible assets, such as its network and contracts, above their book value. These metrics are important for investors assessing the company’s valuation and growth potential in the evolving healthcare landscape.
Additional Sources for BTSG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BTSG Stock Overview
Market Cap in USD | 3,108m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2024-01-26 |
BTSG Stock Ratings
Growth 5y | 52.5% |
Fundamental | 6.05% |
Dividend | 0.0% |
Rel. Strength Industry | 110 |
Analysts | 4.62/5 |
Fair Price Momentum | 20.16 USD |
Fair Price DCF | - |
BTSG Dividends
No Dividends PaidBTSG Growth Ratios
Growth Correlation 3m | 21.3% |
Growth Correlation 12m | 93.7% |
Growth Correlation 5y | 92.3% |
CAGR 5y | 50.13% |
CAGR/Max DD 5y | 1.48 |
Sharpe Ratio 12m | 1.32 |
Alpha | 99.27 |
Beta | 1.26 |
Volatility | 65.31% |
Current Volume | 774.3k |
Average Volume 20d | 1449.9k |
As of March 15, 2025, the stock is trading at USD 17.42 with a total of 774,252 shares traded.
Over the past week, the price has changed by -0.34%, over one month by -21.00%, over three months by -7.73% and over the past year by +111.66%.
Neither. Based on ValueRay Fundamental Analyses, BrightSpring Health is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 6.05 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BTSG as of March 2025 is 20.16. This means that BTSG is currently undervalued and has a potential upside of +15.73% (Margin of Safety).
BrightSpring Health has received a consensus analysts rating of 4.62. Therefor, it is recommend to buy BTSG.
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BTSG BrightSpring Health will be worth about 21.9 in March 2026. The stock is currently trading at 17.42. This means that the stock has a potential upside of +25.95%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 24.7 | 41.7% |
Analysts Target Price | 21.5 | 23.4% |
ValueRay Target Price | 21.9 | 25.9% |